The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for olipudase alfa (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
olipudase alfa
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Powder for injection
Indication
Treatment of Acid sphingomyelinase deficiency (ASMD)
Therapeutic area
Inherited metabolic disorders